The abstract, titled “Bronchiectasis in Sjögren’s Syndrome: Data from the U.S. Bronchiectasis and NTM Research Registry,” compares the demographic, clinical, and microbiologic characteristics of people who have bronchiectasis associated with Sjögren’s syndrome against those who have bronchiectasis without Sjögren’s syndrome. This kind of head-to-head characterization matters because Sjögren’s syndrome, a systemic autoimmune disease best known for its hallmark dryness of the eyes and mouth, is one of the recognized conditions that predispose patients to bronchiectasis. Understanding whether bronchiectasis that develops in the setting of Sjögren’s behaves differently from other forms of the disease could reshape how physicians monitor, treat, and counsel this subgroup of patients.

Bronchiectasis itself is a chronic lung disease defined by airways that have become permanently enlarged, thickened, or scarred. In a healthy respiratory tract, the airways are lined with a mucociliary escalator, a coordinated system of ciliated cells and mucus that traps inhaled microbes and debris and sweeps them upward to be cleared. In bronchiectasis, this architecture is damaged. The permanently widened airways accumulate mucus, and bacteria that would ordinarily be expelled instead linger, multiply, and provoke cycles of inflammation and infection. Each infection cycle can cause further structural damage to the airway walls, creating a self-perpetuating spiral of declining lung function that clinicians describe as a vicious cycle. Between 340,000 and 522,000 adults in the United States are currently receiving treatment for the disease, a figure that many researchers believe underestimates the true burden because bronchiectasis remains underdiagnosed.

Compounding the burden of bronchiectasis is its intimate relationship with nontuberculous mycobacterial pulmonary disease, or NTM lung disease. NTM are a family of mycobacteria commonly found in the environment, in soil and water, that are distinct from the organisms that cause tuberculosis and leprosy. For most people, exposure to these organisms is harmless, but for individuals with compromised immune systems or pre-existing lung conditions such as bronchiectasis or chronic obstructive pulmonary disease, NTM can establish a chronic, difficult-to-treat infection of the lung tissue. NTM lung disease affects tens of thousands of individuals in the United States, and rates of infection are rising. The damaged, mucus-laden airways of bronchiectasis provide an ideal ecological niche for these environmental organisms, which is why the two diseases so frequently appear together and why registries that track both conditions are scientifically valuable.

The data underpinning the CHEST 2026 abstract come from the U.S. Bronchiectasis and NTM Research Registry, an initiative of the Bronchiectasis and NTM Association. The Registry is a national database that collects clinical data from individuals diagnosed with non-cystic fibrosis bronchiectasis and NTM pulmonary disease, the two related conditions that fall outside the well-established cystic fibrosis care infrastructure. Unlike single-center studies, which can reflect the idiosyncrasies of one clinic’s referral patterns and population, the Registry draws participants from multiple clinical institutions across the United States. That multi-center design serves two purposes that researchers in rare-disease fields consistently identify as critical: it supports collaborative research across institutions, and it enables the planning of multi-center clinical trials, which are essential for testing therapies in conditions whose patient populations are dispersed and comparatively small.

The decision to compare Sjögren’s-associated bronchiectasis with non-Sjögren’s bronchiectasis reflects a broader shift in how the field is approaching the disease. Bronchiectasis is not a single entity but an endpoint shared by many different pathways of lung injury: prior severe infections, immune deficiencies, genetic conditions, obstruction of the airways, and autoimmune diseases all can set the vicious cycle in motion. Sjögren’s syndrome stands out among these causes because it combines two mechanisms at once. The autoimmune attack on exocrine glands reduces airway surface moisture and mucus clearance, while the systemic inflammatory environment can directly injure lung tissue. Lymphocytic infiltration of the airways, a well-recognized feature of Sjögren’s, may further alter the inflammatory milieu within the bronchial tree. Whether these mechanisms translate into measurable differences in demographics, clinical course, or the microbiology of the airways is exactly the kind of question the Registry was built to answer.

Demographic, clinical, and microbiologic comparisons are the standard analytical triad in bronchiectasis research, and each axis carries clinical weight. Demographic characteristics, such as age and sex distribution, can reveal whether Sjögren’s-associated bronchiectasis preferentially affects particular populations, which in turn informs screening strategies. Clinical characteristics encompass measures such as lung function, symptom burden, frequency of exacerbations, and the severity of structural damage seen on computed tomography, the imaging modality that serves as the diagnostic cornerstone for bronchiectasis. Microbiologic characteristics describe which organisms colonize or infect the airways, ranging from common bacteria such as Pseudomonas aeruginosa, whose presence is associated with worse outcomes, to the nontuberculous mycobacteria that thrive in damaged airways. A systematic comparison across all three axes can identify whether Sjögren’s-associated disease represents a clinically distinct phenotype, a question with direct implications for how aggressively these patients should be monitored and treated.

The rapid-fire presentation format at CHEST 2026 underscores the pace at which bronchiectasis and NTM research is now moving. For decades, these conditions received limited attention from the pharmaceutical industry and the clinical research establishment, leaving patients with few approved therapies and clinicians with limited evidence to guide care. The maturation of patient registries has been one of the key inflection points in changing that landscape. By systematically collecting longitudinal clinical data from patients across the country, registries convert a scattered population into a research-ready cohort, allowing investigators to characterize disease subgroups, identify unmet needs, and design trials with realistic enrollment targets. Findings presented at major meetings then feed back into clinical practice, shaping which patients physicians think to test for bronchiectasis and which comorbidities they consider when evaluating a chronic cough or recurrent chest infections.

The Bronchiectasis and NTM Association, the nonprofit organization behind the Registry, describes its mission as improving the lives of people with bronchiectasis, NTM lung disease, or both conditions, through education, advocacy, research support, and the advancement of high-quality specialized care. The Association has acknowledged that the Registry is supported in part by corporate donors, a list of which is published on the Supporters page of its website, a transparency practice that is increasingly standard for patient-organization-led research initiatives. For patients living with these chronic conditions, the significance of the CHEST 2026 presentation extends beyond the specific findings about Sjögren’s syndrome. It signals that the experiences captured in the Registry, from hundreds of individuals across multiple institutions, are being translated into knowledge that the pulmonary medicine community is hearing at one of its largest annual gatherings, a step that ultimately moves the field toward better recognition, better trials, and better care.

Subject of Research: Bronchiectasis associated with Sjögren's syndrome compared using the U.S. Bronchiectasis and NTM Research Registry

Article Title: Abstract featuring Bronchiectasis and NTM Research Registry data to be presented at CHEST 2026

Article References: Abstract featuring Bronchiectasis and NTM Research Registry data to be presented at CHEST 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bronchiectasis, NTM lung disease, Sjögren's syndrome, CHEST 2026, patient registry, non-CF bronchiectasis, pulmonary medicine, chronic lung disease, nontuberculous mycobacteria, autoimmune disease, Bronchiectasis and NTM Association, clinical research

One of the headline studies examines a question that has long troubled asthma specialists: whether empiric treatment with chronic proton pump inhibitors, medications routinely prescribed to suppress stomach acid, might actually worsen outcomes in patients with difficult-to-treat asthma. Using a propensity-matched United States cohort design, investigators analyzed biologic-treated patients with difficult-to-treat asthma and found that chronic proton pump inhibitor use was associated with an increased rate of exacerbations. The study does not establish causation, but the association is striking enough to prompt a reevaluation of a common prescribing pattern, particularly in a population already burdened by frequent flare-ups and heavy medication use.

The mechanistic rationale for caution is plausible. Proton pump inhibitors alter gastric pH, which can influence airway inflammation through microaspiration and changes in the microbiome, and prior observational work has suggested links between acid suppression and respiratory infections. In patients whose asthma is already difficult to control and who are receiving biologic therapy, any additional factor that tips the balance toward exacerbation carries clinical weight. The propensity-matching approach used in the study helps control for confounding by indication, since patients prescribed acid suppression often differ systematically from those who are not, but the authors and meeting organizers emphasize that the findings are associative and warrant prospective testing.

A second asthma-adjacent study shifts attention to chronic obstructive pulmonary disease with type 2 inflammation. Mepolizumab, a monoclonal antibody that blocks interleukin-5 and thereby reduces eosinophilic airway inflammation, has an established role in severe eosinophilic asthma. Pooled results from phase 3 randomized trials presented at the meeting indicate that mepolizumab reduces systemic corticosteroid utilization in patients with COPD and evidence of type 2 inflammation. This matters because chronic oral corticosteroid exposure drives a cascade of harms, including osteoporosis, diabetes, weight gain, and increased infection risk, and clinicians have long sought alternatives for the subset of COPD patients with eosinophilic biology.

The pooled analysis aggregates data across multiple phase 3 randomized trials, strengthening statistical power and allowing subgroup patterns to emerge that single trials might miss. For a disease as heterogeneous as COPD, identifying the eosinophilic, type 2 inflammatory phenotype as a treatment-responsive subgroup represents a shift toward precision medicine in an area where broad-spectrum bronchodilation has historically dominated. The results do not suggest mepolizumab for all COPD patients; rather, they support biomarker-guided selection, with blood eosinophil counts and other markers of type 2 inflammation serving as the gatekeepers to biologic therapy.

Bronchiectasis research at the meeting introduces a deceptively simple clinical tool: the color of a patient’s sputum as reported by the patient. In a post hoc analysis from the ASPEN trial, investigators examined whether patient-reported sputum color correlates with objective measures of airway inflammation, specifically neutrophil serine proteases, and with exacerbation risk. The findings suggest that the yellow or green discoloration long noted by clinicians at the bedside reflects real biochemical activity in the airways, since neutrophil-derived enzymes such as myeloperoxidase and neutrophil elastase impart the characteristic green hue through oxidative chemistry involving heme groups.

The ASPEN trial post hoc analysis is notable because it links a subjective, zero-cost patient report to molecular markers and clinical outcomes in a large trial population. If sputum color tracks with neutrophil serine protease activity and predicts exacerbations, it could serve as a practical triage signal in clinics and telemedicine encounters, flagging patients who need intensified anti-inflammatory or antimicrobial treatment before objective laboratory results return. The analysis is post hoc, meaning the endpoint was not the trial’s primary design goal, so the association requires confirmation in prospective studies, but the clinical logic is compelling and the implications for low-resource settings are considerable.

Critical care presentations tackle two of the most consequential questions in intensive care. The first applies machine learning to the problem of extubation failure, the situation in which a patient is removed from mechanical ventilation only to deteriorate and require reintubation within hours or days. Traditional weaning parameters, such as the rapid shallow breathing index and spontaneous breathing trial performance, have limited predictive power, and extubation failure carries significant mortality and morbidity penalties. In an analysis of the MIMIC-IV database, a large publicly available repository of intensive care unit records from Beth Israel Deaconess Medical Center, investigators trained machine learning models to predict extubation failure using features that extend beyond conventional weaning parameters.

The MIMIC-IV analysis exemplifies the current wave of clinical machine learning, in which high-dimensional electronic health record data, including vital signs, laboratory values, medication exposures, and ventilation settings, are mined for patterns invisible to single-parameter rules. Models of this kind can integrate trajectory information, capturing how a patient’s respiratory mechanics evolve over hours rather than relying on a single snapshot. The critical caveats are familiar: retrospective models trained on a single institution’s data risk overfitting and degraded performance on external populations, and algorithmic predictions must be validated prospectively and integrated thoughtfully into clinician decision-making. Still, the direction is clear, and the meeting’s inclusion of this work signals growing institutional interest in augmenting, not replacing, bedside judgment.

The second critical care study addresses telemedicine in the intensive care unit, evaluating tele-ICU implementation and program maturation in urban safety net hospitals through an 18-month multisite interrupted time-series analysis. Safety net hospitals serve disproportionately disadvantaged populations and often operate with constrained staffing, making them ideal test beds for remote intensivist support. Interrupted time-series design is among the strongest quasi-experimental methods available for evaluating health system interventions when randomized assignment is impractical, comparing outcome trajectories before and after implementation while accounting for secular trends. The 18-month horizon also allows the investigators to distinguish early implementation effects from the maturation phase, when teams adapt workflows and trust in the remote system develops.

Tele-ICU programs connect bedside teams with remote critical care specialists who monitor patients, review data, and advise on management around the clock. Evidence on tele-ICU effectiveness has been mixed across prior studies, with some large implementations showing mortality benefits and others showing null results, often attributed to differences in how the programs intervene rather than whether they exist. The new multisite analysis in safety net hospitals adds an equity dimension to this literature, since these institutions care for patients who historically experience worse critical care outcomes. The maturation finding, if it shows improving trajectories over time, would echo prior observations that tele-ICU benefits accrue gradually as integration deepens.

Interstitial lung disease research at the meeting advances two complementary frontiers. The first is noninvasive sphingolipid profiling, which distinguishes idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. These two fibrotic lung diseases can be difficult to differentiate clinically and radiographically, yet they carry different prognoses and treatment pathways, including the eligibility landscape for antifibrotic therapy and the importance of antigen avoidance in hypersensitivity pneumonitis. Sphingolipids, a class of lipid signaling molecules involved in cell proliferation, apoptosis, and inflammatory regulation, have emerged as biomarker candidates in fibrotic disease, and a blood-based profiling approach could spare patients from invasive surgical lung biopsy while accelerating diagnostic clarity.

The second interstitial lung disease study connects telomere biology to imaging. Shorter telomere length, a marker of cellular aging and replicative stress, is a recognized risk factor for pulmonary fibrosis, and telomere-related gene mutations are implicated in familial forms of the disease. The new research reports that shorter telomere length is associated with automated detection of usual interstitial pneumonia on imaging in patients with pulmonary fibrosis. Usual interstitial pneumonia is the histopathologic and radiologic pattern characteristic of idiopathic pulmonary fibrosis, and automated detection algorithms are increasingly capable of quantifying this pattern on high-resolution computed tomography. The association suggests that telomere attrition and the radiologic fingerprint of fibrosis are linked, potentially refining risk stratification in a disease where early identification changes treatment eligibility.

Lung cancer screening, one of the most consequential public health interventions in thoracic medicine, is the subject of a national gap analysis quantifying deficits in awareness, communication, and uptake. Low-dose computed tomography screening reduces lung cancer mortality in high-risk individuals, yet uptake in the United States remains persistently low, with eligible individuals often unaware of their eligibility or never receiving a recommendation from a clinician. The new analysis quantifies these deficits nationally, dissecting where the screening pipeline fails, from public awareness through clinician communication to actual completion of imaging. The framing matters because each stage of the pipeline represents a distinct intervention target, from mass media campaigns to electronic health record prompts that flag eligible patients during routine visits.

Taken together, the CHEST 2026 abstracts portray a specialty in transition, moving from one-size-fits-all approaches toward phenotype-guided therapy, from subjective bedside impressions toward molecular and algorithmic validation, and from fragmented care toward system-level interventions that reach underserved populations. The biologic era is expanding from asthma into COPD and bronchiectasis, machine learning is pressing against the limits of traditional critical care parameters, and lipidomics and telomere biology are reshaping the diagnosis of fibrotic lung disease. Meeting organizers note that all research presented at the meeting is available on the journal CHEST website, and the society emphasizes that the abstracts represent preliminary findings that will inform, but not replace, the peer-reviewed literature and clinical guidelines that follow.

Subject of Research: Research highlights from CHEST 2026 Annual Meeting

Article Title: Research highlights from CHEST 2026 Annual Meeting

Article References: Research highlights from CHEST 2026 Annual Meeting. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: CHEST 2026, pulmonary medicine, critical care, asthma, COPD, bronchiectasis, pulmonary fibrosis, lung cancer screening, tele-ICU, machine learning, Research, highlights

The team, led by Kelsey Haist and Katherine Hisert, compared two mouse models of infection. In one, mice inhaled M. abscessus in liquid suspension, depositing planktonic bacteria in the alveoli, the thin-walled air sacs where gas exchange occurs. In the other, bacteria were embedded in agar beads roughly 100 to 200 micrometers in diameter, which lodge in small airways when instilled into the oropharynx. The bead model has been refined over decades for studying chronic opportunistic infections, and it reproduces several features of human bronchiectasis: focal airway obstruction, reduced mucociliary transport, localized hypoxia with expression of hypoxia-inducible factor 1 alpha, and lung pathology that closely resembles what clinicians see in patients with chronic M. abscessus disease.

The contrast in outcomes was stark. Mice given planktonic bacteria carried more than a thousand-fold fewer organisms by two weeks after infection, and virtually all had cleared the infection by three weeks. Mice infected with bacteria-laden beads, by contrast, maintained bacterial loads near the size of the initial inoculum at two weeks, and more than half still harbored detectable bacteria at six weeks. Most bead-infected mice eventually cleared the organism by ten to sixteen weeks, but the kinetics were slow and heterogeneous, echoing the protracted course of human disease. Histology revealed acid-fast bacilli persisting within remnants of infected beads at two weeks, and granulomatous structures that endured even after bacterial clearance, only beginning to resolve by sixteen weeks.

Flow cytometry of digested lung tissue and bronchoalveolar lavage fluid exposed a fundamentally different immune landscape in the two models. During the first two weeks of bead infection, absolute numbers of neutrophils in the lungs rose sharply and far exceeded the modest neutrophil influx seen with alveolar infection, while the relative abundance of recruited macrophages was lower. Bronchoalveolar lavage at two weeks showed roughly tenfold more neutrophils in bead-infected mice than in mice given planktonic bacteria. Notably, the sterile beads themselves provoked little inflammation, indicating that the intense neutrophilic response required living bacteria rather than obstruction alone. Yet the paradox remained: despite this robust cellular recruitment, bacteria persisted far longer in the airways than in the alveoli.

The resident alveolar macrophages themselves behaved differently depending on the infection site. These long-lived, self-renewing cells, identifiable by markers including Siglec-F and CD11c, are normally found in the alveolar spaces. In bead-infected mice, most resident alveolar macrophages upregulated CD11b, a surface marker of inflammatory activation, by one week after infection and maintained high expression at three weeks, even though the infection was confined to the airways rather than the alveoli. The authors suggest two possible explanations: bacterial debris and organisms shed from degrading beads may filter down into the alveoli, or the macrophages may respond to inflammatory cytokines released by stressed epithelial cells and recruited neutrophils throughout the inflamed lung.

To test whether these activated cells actually mattered for bacterial control, the researchers depleted resident alveolar macrophages using clodronate-loaded liposomes delivered oropharyngeally one day before infection. The depletion was rapid and sustained, eliminating more than ninety percent of the cells. In alveolar infection, the consequence was immediate: mice lacking resident alveolar macrophages carried tenfold more bacteria at three days after infection than control mice, demonstrating that these cells are essential for containing early bacterial replication in the air sacs. The depleted mice eventually regained control, likely through a compensatory flood of neutrophils and blood-derived macrophages into the airspaces, but their bacterial burdens remained elevated throughout the ten-day observation period.

In the bead model, the same depletion produced no effect whatsoever on bacterial burden over fourteen days. Mice without resident alveolar macrophages controlled airway infection just as well as intact mice, and the magnitude of neutrophil recruitment was unchanged. The only detectable difference was a modest increase in recruited macrophages in the lavage fluid of depleted mice, possibly reflecting monocytes entering the alveoli to replace the ablated resident population. The implication is striking: the immune cell that matters most in the alveoli is not the one that matters in the obstructed airway, where other players, presumably recruited neutrophils and monocyte-derived macrophages acting within a very different microenvironment, take over the task of bacterial containment.

These findings align with a growing literature on macrophage heterogeneity. Work in fruit flies, zebrafish, and other models has consistently shown that macrophages are critical for controlling M. abscessus, and prior mouse studies using both liposome depletion and genetic ablation confirmed the importance of resident alveolar macrophages for alveolar infection. But macrophage phenotypes are shaped by their local tissue environment, by pathogen-associated and damage-associated molecular patterns, and by cues from neighboring cells. The new study extends this principle across lung compartments: alveoli and airways are anatomically continuous, yet they generate overlapping but distinct immune responses to the same pathogen.

The results also mirror observations in human patients. Studies of sputum and lung samples from people with bronchiectasis and chronic obstructive pulmonary disease find that airway immune cells are largely recruited from the blood, with resident alveolar macrophages minimally represented or absent. The bead-infected mice recapitulate this pattern, lending confidence that the model captures relevant features of human disease. The authors caution, however, that their analysis focused on the first two weeks and on myeloid cells; lymphocytes became more prominent later and participated in granuloma formation, and the study could not fully distinguish whether the altered response stems from the airway location itself or from the obstruction, epithelial stress, and hypoxia that accompany it.

The broader significance lies in therapy development. Current antibiotic regimens for M. abscessus lung disease last months to years, carry substantial side effects, and frequently fail, partly because laboratory susceptibility testing does not reflect how bacteria behave within living tissue. Understanding which macrophage populations occupy the infection site, and how the airway niche alters bacterial metabolism and host-pathogen interactions, could guide host-directed therapies designed to bolster the right defenses in the right compartment. As the authors conclude, characterizing the immune milieu of damaged airways may ultimately reveal why some infections resolve while others become chronic, and how medicine might tip that balance in favor of the patient.

Subject of Research: Differential roles of resident alveolar macrophages in controlling alveolar versus airway Mycobacterium abscessus infection in mice

Article Title: Differential roles of resident lung macrophages during control of murine alveolar and airway Mycobacterium abscessus infection

Article References: Haist, K. C., Congel, J. H., Corley, J. M., Ochoa, A. E., McClendon, J., Hume, P. S., Nick, J. A., Janssen, W. J., Malcolm, K. C., & Hisert, K. B. (2026). Differential roles of resident lung macrophages during control of murine alveolar and airway Mycobacterium abscessus infection. Frontiers in Tuberculosis, 4, Article 1781507. https://doi.org/10.3389/ftubr.2026.1781507

Image Credits: AI Generated

DOI: 10.3389/ftubr.2026.1781507

Keywords: Mycobacterium abscessus, nontuberculous mycobacteria, alveolar macrophages, bronchiectasis, cystic fibrosis, lung immunity, agar bead infection model, neutrophils, macrophage depletion, clodronate liposomes, chronic lung infection, host-directed therapy

The epidemiological significance of NTM diseases was not fully appreciated until the early 1950s, many decades after Robert Koch announced the discovery of Mycobacterium tuberculosis in 1882. It was not until the mid-1980s that clinicians described the non-classic, nodular-bronchiectatic form of NTM pulmonary infection, distinguishing it from the previously recognized classic, cavitary presentation. By the late 1980s, bronchiectasis itself was still regarded as an orphan disease. Since then, the field has rapidly evolved into one of the fastest-growing areas of interest in respiratory medicine, yet research on NTM infections continues to lag markedly behind that devoted to tuberculosis.

The Research Topic curated by the editorialists includes one review exploring the cause-and-effect relationship between the two conditions, a case report of infection caused by the uncommon species Mycobacterium colombiense that led to the development of bronchiectasis, and three original research articles. The first study examines the epidemiology of NTM infection and concludes that the available evidence does not support person-to-person transmission. The second analyzes differences in granuloma formation induced by M. tuberculosis and M. avium. The third describes a murine model that replicates key features of cystic fibrosis, a condition closely associated with the development of bronchiectasis.

Rubio and colleagues investigated pathogen transmission by analyzing the cluster structure of 46 M. avium complex isolates obtained from patients with bronchiectasis, using whole-genome sequencing. Bronchiectasis provides a favorable environment for mycobacterial proliferation and facilitates their expulsion from the lungs through coughing. The researchers identified two clusters, each composed of two strains from different patients, isolated more than a year apart and without any evident epidemiological link, prompting the conclusion that person-to-person transmission had not occurred. If these strains share a common ancestor, the mode of transmission remains unresolved and is likely to involve indirect routes such as fomites, an area currently under active investigation. This study also offers valuable insights into the genomic diversity of M. intracellulare and M. avium species.

Among the species most frequently isolated today are M. avium, M. intracellulare, and M. abscessus. New NTM species, however, continue to be identified in clinical settings. An interesting example is the case reported by Tan and colleagues, describing the isolation of M. colombiense, a member of the M. avium complex, from a patient with bronchiectasis. Taken together, this and other cases reported in the scientific literature suggest that bronchiectasis, initially associated primarily with M. avium infection, can develop in the context of infection by a wide range of mycobacterial species. The authors highlight the need for heightened surveillance for NTM in bronchiectasis patients. It remains uncertain whether any mycobacterial species, including those not previously associated with human disease, are capable of inducing bronchiectasis in a susceptible host. Notably, the genus Mycobacterium contains more recognized pathogenic species than any other bacterial genus.

Once in the lungs, if innate immunity fails to halt the multiplication of the bacilli, granuloma formation may ensue. Granulomas arising from NTM infection often appear on imaging as pulmonary nodules, a hallmark of the nodular-bronchiectatic form of the disease. It remains unclear which specific granuloma-associated factors drive cavity formation in tuberculosis, whereas NTM infections are more commonly associated with nodules and bronchiectasis. Doratte and colleagues address this important question by comparing tuberculous and non-tuberculous granulomas in a highly relevant primate model. Their findings show that M. tuberculosis-induced granulomas display a more aggressive and destructive profile, whereas those formed in response to M. avium exhibit signaling patterns that maintain granuloma integrity. This more stable granuloma structure may help shield the mycobacteria, promoting their persistence and the progression to chronic disease, a process in which radiologic findings may evolve from isolated nodules to established bronchiectasis.

The genetic disease most strongly associated with bronchiectasis is cystic fibrosis, caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride and bicarbonate channel that balances fluid homeostasis in epithelia. In the airways, mucus becomes dehydrated and mucociliary clearance is severely impaired, creating conditions that facilitate infection by a variety of microorganisms, including mycobacteria. A cystic fibrosis-like phenotype can be reproduced in mice by mutating the βENaC channel, which enhances sodium transport. Given that nearly all patients with cystic fibrosis eventually develop bronchiectasis, this model was used by Pearce and colleagues to examine the role of M. abscessus, an NTM species frequently isolated in this population. The results showed that the mice were able to clear the mycobacteria, leading to the conclusion that this model is not suitable for studying chronic infection. Nevertheless, a decline in lung function was observed, suggesting that the model may still be useful for investigating the early stages of bronchiectasis development, a possibility that warrants further study.

The review by Singh and colleagues may serve as a compendium of the subject matter covered in this Research Topic. The authors describe the vicious cycle that arises between NTM infection and bronchiectasis. NTM infection fuels persistent inflammation and tissue damage through cytokine release and granulomatous responses, leading to further architectural distortion of the airways and progression of bronchiectasis. In turn, the structural abnormalities and impaired mucociliary clearance characteristic of bronchiectasis increase susceptibility to NTM acquisition, perpetuating the cycle. The authors also emphasize other key aspects of the disease, such as the diagnostic challenges faced in high-burden countries, where smear microscopy cannot distinguish M. tuberculosis from NTM, making molecular methods essential, as well as the difficulty of differentiating true infection from mere colonization. According to international guidelines, confirmation of NTM pulmonary disease requires a combination of clinical symptoms, radiological abnormalities, and microbiological evidence, including at least two positive sputum cultures or one positive bronchoscopy sample. The importance of biofilm formation is also stressed, as it promotes microbial persistence and facilitates horizontal gene transfer, thereby potentially increasing antimicrobial resistance and complicating treatment.

The association between NTM infection and bronchiectasis affects an ever-growing number of patients, yet many aspects of their interplay remain poorly understood. The simultaneous rise in the incidence of both conditions is unlikely to be coincidental and may instead reflect a close and biologically meaningful connection. Moreover, the proportion of infections that progress to bronchiectasis and the proportion of pre-existing structural airway abnormalities that predispose to infection are unlikely to be equivalent. In each scenario, the therapeutic priorities would differ, creating opportunities for more tailored and personalized treatment strategies. As research continues to unravel the complex interplay between these mycobacteria and the structurally compromised lung, the editorial underscores the need for continued vigilance, improved diagnostics, and a deeper mechanistic understanding to guide future clinical practice.

Subject of Research: The relationship between non-tuberculous mycobacterial infection and bronchiectasis

Article Title: Editorial: Non-tuberculous mycobacteria and bronchiectasis

Article References: Rivero-Lezcano, O. M., López-Medrano, R., & Esteban, J. (2026). Editorial: Non-tuberculous mycobacteria and bronchiectasis. Frontiers in Tuberculosis, 4, Article 1819209. https://doi.org/10.3389/ftubr.2026.1819209

Image Credits: AI Generated

DOI: 10.3389/ftubr.2026.1819209

Keywords: non-tuberculous mycobacteria, bronchiectasis, Mycobacterium avium complex, Mycobacterium abscessus, cystic fibrosis, granuloma, whole-genome sequencing, mucociliary clearance, pulmonary infection, CFTR, biofilm, epidemiology

Externally-led meetings of this kind occupy a distinctive position in the regulatory landscape. While the FDA convenes its own patient-focused meetings for selected conditions, patient organizations can also host externally-led versions that follow the same structured approach, inviting patients, caregivers, clinicians, drug developers, and regulators to a common forum. In this case, the Association has confirmed that drug developers, the FDA, and other stakeholders will be in attendance, meaning that the testimony gathered during the proceedings will reach precisely the audiences capable of acting on it. The goal is not simply to document suffering but to convert personal narratives into structured evidence that can inform clinical trial design, endpoint selection, benefit-risk assessment, and regulatory decision-making for years to come.

Non-cystic fibrosis bronchiectasis is a chronic lung disease characterized by persistent inflammation and chronic infection, in which the airways become abnormally widened, thickened, or scarred. This structural damage impairs the lungs’ ability to clear mucus, creating a vicious cycle in which retained secretions harbor bacteria, bacterial colonization drives further inflammation, and ongoing inflammation deepens the airway injury. Patients typically experience chronic cough, copious sputum production, recurrent respiratory infections, breathlessness, and profound fatigue. Exacerbations, the acute worsening episodes that punctuate the disease’s course, can force hospitalization and are associated with accelerated loss of lung function over time. The daily burden of managing airway clearance, antibiotics, and the psychological weight of a lifelong condition is substantial and often invisible to those outside the patient community.

For decades, the disease was considered rare, a classification that shaped nearly every aspect of the research and treatment environment surrounding it. Rare disease status typically means small patient populations, fragmented clinical data, limited commercial incentives for drug development, and lengthy diagnostic delays. As the Association notes, however, the picture has changed considerably in recent years. Growing awareness, expanded research activity, and advances in imaging, particularly high-resolution computed tomography, have dramatically improved the ability of clinicians to recognize and characterize the disease. Epidemiological studies across multiple countries have suggested that bronchiectasis is more common than previously appreciated, particularly among older adults, and the condition is now recognized more widely throughout the medical community. This shift in recognition has laid the groundwork for the therapeutic progress now beginning to emerge.

That progress reached a watershed moment in 2025, when the first FDA-approved treatment for non-cystic fibrosis bronchiectasis became available. The approval ended a long era in which patients and their physicians had to rely entirely on off-label approaches, borrowed from cystic fibrosis care or general respiratory medicine, to manage a disease with its own distinct biology. Yet the Association is careful to frame this milestone as a beginning rather than an endpoint. Many people with the condition still face delays in diagnosis, limited access to specialized care, and persistent difficulties managing the disease’s daily impact. A single approved therapy, however significant, cannot address the full spectrum of patient needs, and the Association’s announcement makes clear that significant unmet needs remain across the community.

The planned meeting has been structured around three explicit objectives. First, it aims to enhance understanding of how living with non-cystic fibrosis bronchiectasis impacts daily life experiences, capturing dimensions of the disease that conventional clinical measures often miss. Second, it seeks to capture diverse perspectives from across the NCFB community in order to foster timely and effective therapy development, ensuring that the pipeline reflects the heterogeneity of the patient population rather than a narrow slice of it. Third, it intends to inform regulatory decision-making with insights on current care and treatment benefit needs, giving reviewers and policymakers a grounded picture of what patients would consider meaningful improvement. Together, these objectives reflect a maturing philosophy in drug development: that patient input is not anecdote but data.

Elisha Malanga, Executive Director of the Bronchiectasis and NTM Association, emphasized the significance of the moment in a statement accompanying the announcement. The first FDA-approved treatment for the disease marked an important milestone, she said, but significant unmet needs remain, and the daily burden of the disease continues to affect many people living with the condition. She described the initiative as an important opportunity to ensure that the voices of people living with non-cystic fibrosis bronchiectasis are heard by the FDA, researchers, and treatment developers, and she noted that by sharing their experiences, challenges, and priorities, community members can help shape a deeper understanding of the disease and inform the development of future treatments that address what matters most to them.

The meeting itself is proposed for late 2027, a timeline that gives the Association and its partners ample opportunity to prepare. Crucially, the event will include a virtual element, a design choice intended to ensure accessibility for all attendees regardless of geography, health status, or mobility. This consideration matters enormously for a lung disease community in which many patients manage chronic infection and fatigue that can make travel difficult or risky. The Association has committed to engaging a wide array of NCFB community stakeholders in support of the initiative, and additional information about the meeting, including details on participation, will be released at a later date. The extended runway also allows time for structured pre-meeting surveys and outreach, tools commonly used in patient-focused drug development to reach patients who cannot attend live sessions.

The broader significance of the announcement extends beyond a single disease community. Patient-focused drug development has become one of the most consequential shifts in modern regulatory science, reflecting a growing consensus that clinical trial endpoints must align with outcomes patients actually value. For a condition like non-cystic fibrosis bronchiectasis, where exacerbation frequency, symptom burden, and quality of life are central to the patient experience, systematically collected patient input can help sponsors design trials that measure what matters, potentially shortening development timelines and improving the odds that approved therapies deliver tangible benefit. It can also help regulators weigh benefits and risks in ways that reflect real-world priorities rather than surrogate measures alone.

For the bronchiectasis and NTM community, the announcement represents both recognition and momentum. An organization founded to serve patients with two closely related and long-neglected conditions is now convening the full machinery of drug development, from regulators to industry, around the testimony of the people who live with the disease every day. If the meeting fulfills its stated aims, the experiences shared in late 2027 could echo through trial protocols, regulatory reviews, and ultimately treatment options for a patient population that has waited far longer than most for therapies designed specifically for them. Additional details about the meeting will be announced by the Association as planning progresses.

Subject of Research: An externally-led patient-focused drug development meeting for non-cystic fibrosis bronchiectasis announced by the Bronchiectasis and NTM Association.

Article Title: Bronchiectasis and NTM Association announces Externally-Led Patient-Focused Drug Development meeting for non-cystic fibrosis bronchiectasis

Article References: Bronchiectasis and NTM Association announces Externally-Led Patient-Focused Drug Development meeting for non-cystic fibrosis bronchiectasis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bronchiectasis, NTM, NCFB, PFDD, FDA, drug development, patient advocacy, lung disease, clinical research, regulatory decision-making, COPD Foundation, rare disease

The scale of the underlying data is itself noteworthy. The team conducted ancestry-specific meta-analyses of genome-wide association studies, or GWAS, in Europeans and East Asians separately, and then pooled the results in a joint trans-ancestry meta-analysis encompassing 16,030 bronchiectasis cases and 1,841,141 controls. This design matters because genetic architectures can differ subtly between populations, and combining ancestries increases both statistical power and the chances of detecting variants that are rare or population-specific. The ancestry-specific analyses identified five bronchiectasis lead loci in Europeans and one in East Asians, while the trans-ancestry analysis converged on five lead signals, the strongest of which was a variant known as rs28929474, annotated to the gene SERPINA1.

That top hit is biologically compelling. SERPINA1 encodes alpha-1 antitrypsin, a protease inhibitor whose deficiency is already a well-established cause of both emphysema and bronchiectasis. The fact that the strongest cross-ancestry signal lands squarely on this gene provides a satisfying validation of the study’s methodology: the analysis is not merely generating statistical noise but recovering biology that clinicians already recognize, while simultaneously extending it to new candidates. It also underscores the value of including diverse populations, since signals that might be diluted or absent in one ancestry can emerge clearly when data from multiple ancestries are integrated.

Identifying lead variants is only the first step in modern disease genetics, because a single genomic region can contain dozens of correlated variants that travel together through inheritance, a phenomenon known as linkage disequilibrium. To disentangle which variants are most likely to be the true causal drivers, the researchers performed statistical fine-mapping, a computational approach that weighs each candidate variant’s association strength and correlation structure to produce credible sets of plausible culprits. This procedure yielded two credible sets in the European analysis and three in the trans-ancestry analysis, narrowing the field of candidate causal variants considerably and providing a more precise starting point for functional follow-up.

Perhaps the most innovative layer of the study is its use of proteome-wide Mendelian randomization based on cis-protein quantitative trait loci, or cis-pQTLs. Mendelian randomization exploits naturally occurring genetic variants as instruments to test whether a causal relationship exists between an exposure, in this case the circulating level of a specific protein, and a disease outcome. Because genetic variants are randomly allocated at conception, this approach is largely immune to the confounding and reverse causation that plague observational epidemiology. By restricting instruments to variants near the gene encoding each protein, the researchers reduced the risk of pleiotropic artifacts. In the European data, this analysis, combined with colocalization tests that verify whether the same variant drives both protein levels and disease risk, prioritized AIF1 and WWP2 as candidate proteins for bronchiectasis. The corresponding East Asian analyses nominated HSPA1A and DXO.

These protein candidates span intriguing biology. AIF1, also known as allograft inflammatory factor 1, is involved in immune cell activation and inflammatory signaling, processes central to the chronic neutrophilic inflammation that characterizes bronchiectatic airways. WWP2 is an E3 ubiquitin ligase with roles in protein degradation and developmental signaling pathways, including those governing airway epithelial biology. HSPA1A encodes a heat shock protein that orchestrates cellular stress responses, while DXO participates in RNA processing and quality control. That different ancestries surfaced different candidate proteins is not necessarily a weakness of the study; rather, it may reflect genuine population-level differences in disease mechanisms, differing allele frequencies, or differences in the protein quantitative trait loci resources available for each group. Each candidate now represents a hypothesis that can be tested experimentally in cellular and animal models of airway disease.

The team also applied transcriptome-wide association studies, or TWAS, which ask whether genetically predicted expression of a gene in a specific tissue, here the lung, is associated with disease risk. Integrated with colocalization analysis to ensure the expression signal and the disease signal share the same underlying variant, the lung TWAS in Europeans prioritized CHP2 and FUBP1. CHP2 is a calcineurin homologous protein implicated in ion transport and cell proliferation pathways, while FUBP1 is a far upstream element binding protein that regulates transcription and, notably, has been linked to the expression of CFTR, the chloride channel whose mutations cause cystic fibrosis, itself the classic cause of bronchiectasis. This convergence of transcriptomic and proteomic evidence with known airway biology strengthens confidence that the prioritized targets are not statistical artifacts.

Beyond bronchiectasis in isolation, the study tackled a question of considerable clinical importance: why do bronchiectasis, COPD, asthma, and chronic bronchitis so frequently coexist in the same patients? The researchers quantified genetic correlation between bronchiectasis and these overlapping conditions, then performed cross-disease pleiotropic analyses to identify variants influencing more than one disease. This effort highlighted shared signals at SERPINA1, SMAD3, CFTR, and PHTF1, with additional support for SMAD3 coming from blood cis-eQTL-based Mendelian randomization and colocalization. SMAD3 is a central transducer of the TGF-beta signaling pathway, which regulates airway remodeling and fibrosis, and variants in SMAD3 are known to contribute to thoracic aortic disease with features overlapping connective tissue disorders. CFTR, as the cystic fibrosis gene, needs little introduction in this context, and its appearance among the shared signals reinforces the idea that impaired airway surface hydration and mucociliary clearance form a common mechanistic thread linking several chronic airway diseases.

The implications for drug development are tangible. Bronchiectasis currently lacks mechanism-informed therapies; management relies largely on airway clearance techniques, antibiotics for infective exacerbations, and treatment of underlying causes where they can be identified. By prioritizing proteins and genes whose genetically determined levels or expression influence disease risk, the study provides a shortlist of targets that pass some of the most stringent causal filters available in human genetics. Drugs aimed at proteins with human genetic evidence of disease relevance have historically shown higher success rates in clinical trials, and the multi-omics triangulation used here, spanning GWAS, fine-mapping, pQTL-based and eQTL-based Mendelian randomization, TWAS, and colocalization, is precisely the kind of evidence stack that pharmaceutical target selection increasingly demands.

Caveats remain, as they must in any genetics-first study. The analyses relied on summary-level data from previously generated studies, which means individual-level covariates, environmental exposures, and disease subphenotypes could not be modeled directly. Protein and expression quantitative trait loci resources differ in depth between ancestries, and the candidate targets nominated in East Asians and Europeans will require replication in additional cohorts and functional validation before they inform clinical practice. Nevertheless, the study marks a clear advance: it refines the cross-ancestry genetic architecture of bronchiectasis, confirms the centrality of protease-antiprotease imbalance through SERPINA1, and elevates a set of new molecular suspects, from AIF1 and WWP2 to CHP2 and FUBP1, into the spotlight of translational respiratory research. For a disease that has waited decades for precision-medicine attention, the genetic map is finally beginning to fill in.

Subject of Research: Cross-ancestry genetic architecture of bronchiectasis and multi-omics prioritization of candidate molecular drug targets

Article Title: Cross-ancestry bronchiectasis GWAS meta-analysis and multi-omics integration prioritize candidate molecular targets

Article References: Miao, K., Li, D., Cai, S., & Hong, X. (2026). Cross-ancestry bronchiectasis GWAS meta-analysis and multi-omics integration prioritize candidate molecular targets. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09081-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09081-2

Keywords: bronchiectasis, GWAS, meta-analysis, Mendelian randomization, SERPINA1, pQTL, TWAS, colocalization, COPD, asthma, chronic bronchitis, drug targets

The biological concept at the heart of the review is cellular senescence, a state in which cells stop dividing but refuse to die, instead secreting a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype, or SASP. Senescence is not inherently harmful; it contributes to wound healing and tumor suppression in the short term. But when senescent cells accumulate with age, their secretions chronically inflame surrounding tissue, degrade its structure, and push neighboring cells toward senescence themselves. The review argues that EVs act as essential shuttles in this process, propagating senescence signals between cells and creating what the authors describe as a vicious cycle of senescence, inflammation, and dysfunction. In the words of first author Professor Wang, cellular senescence is a major driver of many chronic pulmonary conditions, and EVs are the vehicles that carry those instructions from cell to cell.

Crucially, the cargo of an extracellular vesicle depends on the state of the cell that released it. Under healthy conditions, EVs help maintain tissue homeostasis, supporting immune regulation, cell proliferation, and repair. In disease states, however, senescent cells package a distinctly pro-senescent payload. When neighboring healthy cells take up these vesicles, they can be driven into secondary senescence, amplifying inflammation, tissue damage, and fibrosis across the lung. This mechanism helps explain why chronic lung diseases track so closely with aging, and why damage, once established, tends to spread and self-perpetuate even after the original insult, such as cigarette smoke or environmental pollutants, has been removed.

The review details several mechanistic pathways through which EVs accelerate disease. They facilitate aberrant intercellular communication, deliver pathogenic microRNAs and proteins, promote chronic inflammation, modulate immune cell function, amplify oxidative stress, and actively contribute to remodeling of the extracellular matrix, the scaffolding that gives lung tissue its elastic architecture. Among all cargo types, microRNAs have attracted the most attention because a single vesicle can deliver molecules that silence multiple target genes at once. Several miRNAs in particular, including miR-34a, miR-21, miR-125a-5p, miR-146a-5p, and miR-570-3p, have been shown to target key anti-aging molecules such as the sirtuins, a family of enzymes that protect cells against stress and maintain genomic stability, thereby accelerating senescence in epithelial cells and fibroblasts.

Disease-specific examples illustrate how finely tuned, and how varied, these mechanisms are. In COPD, small EVs released by airway epithelial cells transfer miR-34a to recipient cells, where it suppresses SIRT1, raising levels of the cell-cycle inhibitor p21 and other senescence markers. In idiopathic pulmonary fibrosis, a relentlessly scarring disease of the lung interstitium, fibroblast-derived EVs deliver miR-23b-3p and miR-494-3p, which downregulate SIRT3 and trigger mitochondrial dysfunction, reinforcing the pro-fibrotic, pro-senescent microenvironment that characterizes the disease. In asthma, EV-mediated alterations in miR-34a may simultaneously influence immune polarization and cellular aging pathways in the airway, linking two processes usually studied in isolation.

The review extends this framework to conditions that receive less attention in senescence research. In bronchiectasis, sputum-derived miR-92b-5p and miR-223-3p may directly connect colonization by the bacterium Pseudomonas aeruginosa to airway aging, mediating local inflammation through the cytokines IL-1β and IL-8 while regulating longevity-related pathways. In obstructive sleep apnea, EVs have been implicated in the cardiovascular and neurocognitive complications that accompany repeated nighttime oxygen deprivation. In lung cancer, EVs remodel the tumor microenvironment and mediate resistance to therapy, adding a senescence dimension to oncology’s long-standing interest in vesicle biology. The authors argue that this functional diversity across diseases underscores the pivotal position EVs occupy in the regulatory network of pulmonary medicine.

What elevates the review beyond mechanism is its treatment of EVs as therapeutic agents in their own right. Because they are naturally derived, inherently biocompatible, and capable of targeted delivery, EVs have emerged as promising drug carriers. Mesenchymal stem cell-derived EVs have shown the potential to alleviate inflammation, downregulate senescence markers, and repair lung tissue in experimental models of COPD and IPF. Neutrophil-derived EVs offer unique advantages as delivery vehicles, and aerosol administration allows vesicles to be delivered efficiently and noninvasively directly to lung tissue, a route particularly suited to respiratory disease. In early clinical translation, research in COPD has focused on plasma exosomal miRNA biomarkers, while lung cancer studies apply EV-based liquid biopsy to guide therapeutic decisions. Although these studies were not designed specifically to target senescence, the authors note that they provide indirect evidence for the mechanisms underlying EV-mediated pulmonary aging.

Professor Wang notes that EVs hold promise as tools for senotherapy, the emerging class of interventions aimed at removing or reprogramming senescent cells, and that developing optimal EVs for such therapies is becoming an important research focus. Current optimization strategies include loading vesicles with therapeutic drugs, modifying their surfaces with targeting ligands so they home to specific cell types, and refining aerosol delivery for the respiratory tract. Yet significant obstacles stand between laboratory promise and bedside impact. Isolation and characterization methods remain inconsistent across laboratories, making results difficult to compare and reproduce. Large-scale clinical validation is still lacking, and the basic biology of EVs in the aging context, including how vesicle cargo changes with age and disease severity, is only beginning to be mapped.

The significance of the review lies in its unifying framing. Chronic lung diseases have traditionally been studied and treated as separate entities, each with its own specialist clinic, biomarker panel, and drug pipeline. By identifying EV-mediated senescence signaling as a shared pathway running through COPD, IPF, asthma, bronchiectasis, OSA, and lung cancer, the authors provide a conceptual bridge that could allow insights and therapies developed for one condition to inform others. A vesicle-targeting strategy that interrupts the transfer of miR-34a in COPD airways, for example, might be adapted to interrupt pro-fibrotic vesicle signaling in IPF. Conversely, biomarkers measured in circulating vesicles could one day track senescence burden across multiple diseases with a single blood test.

The work also arrives at a moment when the biology of aging is moving from the fringes of medicine toward its center. With global populations aging rapidly, the burden of chronic respiratory disease is projected to rise steeply, and current treatments largely manage symptoms rather than halt the underlying degenerative process. If EVs truly are the shuttles that spread senescence through lung tissue, then intercepting them, disarming their cargo, or replacing them with engineered vesicles carrying restorative payloads represents a fundamentally new therapeutic paradigm. The review’s authors are careful to emphasize the challenges that remain, but their synthesis offers researchers a clear framework for future investigation and, they hope, a path toward anti-senescence therapy for chronic respiratory diseases that changes the trajectory of these conditions rather than merely slowing their symptoms.

Subject of Research: The role of extracellular vesicles in cellular senescence and chronic lung diseases

Article Title: Insights into extracellular vesicles in senescence-associated chronic lung diseases

Article References: Insights into extracellular vesicles in senescence-associated chronic lung diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: extracellular vesicles, cellular senescence, COPD, idiopathic pulmonary fibrosis, microRNAs, SASP, sirtuins, senotherapy, asthma, lung cancer, bronchiectasis, obstructive sleep apnea

ANCA-associated vasculitis, or AAV, is a family of necrotizing small-vessel diseases driven by pathogenic antineutrophil cytoplasmic antibodies. It encompasses microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis. Classically, patients present with striking systemic features—rapidly rising creatinine, pulmonary hemorrhage, palpable purpura, peripheral neuropathy—that trigger an immunological workup and serological testing. Bronchiectasis, by contrast, is rarely considered an inaugural manifestation. When it appears in AAV, it is usually interpreted as structural fallout from established vasculitic inflammation rather than a warning shot, a framing that can postpone ANCA testing until organ damage declares itself elsewhere.

The patient at the center of the report arrived in 2018 with a chronic productive cough and a history of intermittent asthma. High-resolution computed tomography revealed focal bronchiectasis confined to the right middle lobe. Her physicians did what good diagnosticians do: they systematically excluded the usual suspects. Serial sputum cultures and bronchoalveolar lavage were negative for bacterial, mycobacterial, and fungal pathogens. Non-tuberculous mycobacterial infection, cystic fibrosis, primary immunodeficiency, allergic bronchopulmonary aspergillosis, and eosinophilic granulomatosis with polyangiitis were all ruled out. Spirometry was normal. Empiric corticosteroids and macrolides were prescribed for presumed non-infective airway inflammation, and her symptoms improved—but never resolved.

Over the following six years, repeat imaging charted a slow, ominous march. The focal right middle lobe disease progressed to multifocal bilateral bronchiectasis, accompanied by tree-in-bud nodularity and mucus plugging, with new parenchymal nodules appearing along the way. Her antinuclear antibody test was negative. Critically, ANCA serology was never obtained, and the diagnosis remained bronchiectasis of undetermined etiology for seven years. The authors of the report are careful not to overclaim causality, but they highlight a stark, narrower fact: seven years elapsed during which an inexpensive blood test that would have reframed the entire diagnosis was never sent.

Then, in 2025, the systemic disease erupted. The woman developed palpable purpura across both lower extremities, hemoptysis, and hematuria. Imaging showed new multifocal bilateral consolidations superimposed on the established bronchiectasis, though without the ground-glass pattern of diffuse alveolar hemorrhage; her hemoglobin and oxygen saturation remained stable and the hemoptysis resolved spontaneously. Her kidneys told a more urgent story. Serum creatinine had surged from 0.46 mg/dL six weeks earlier to 2.09 mg/dL—an estimated glomerular filtration rate collapsing from 100 to 24 mL/min/1.73 m²—and reached a nadir of 2.19 mg/dL on hospital day three, all while urine output remained preserved.

The serology finally caught up with the disease. Indirect immunofluorescence showed a perinuclear pattern, and antigen-specific ELISA confirmed myeloperoxidase-ANCA, or MPO-ANCA, at 250.2 U/mL against a reference value below 1.0, with proteinase 3-ANCA negative. Urinalysis revealed proteinuria with dysmorphic erythrocytes. A renal biopsy sampling fourteen glomeruli showed pauci-immune crescentic glomerulonephritis with a cellular crescent in one glomerulus, no immune deposits, and more than half of the glomeruli intact—Berden focal class, the histological category carrying the most favorable prognosis. Anti-glomerular basement membrane and anti-double-stranded DNA antibodies were negative, and complement was normal. Together, the findings established microscopic polyangiitis.

Treatment followed current guidelines: three days of intravenous methylprednisolone at 500 mg daily, an oral prednisone taper, and rituximab 1 gram repeated after two weeks and then every six months as maintenance, with Pneumocystis prophylaxis. The response was dramatic on the inflammatory front. Within two months her eGFR peaked at 74, stabilizing at 60 at fifteen months—stage 3a chronic kidney disease, a plateau the authors attribute to residual nephron loss after inflammatory suppression. At five months, high-resolution CT showed near-complete resolution of the consolidations, while the underlying bronchiectasis persisted, exactly as expected for fixed structural airway damage. MPO-ANCA fell from 250.2 to 5.2 U/mL by twelve months with documented B-cell depletion, and she remains asymptomatic at fifteen months, her cough finally resolved.

The literature review embedded in the report gives the case its wider significance. A 2024 systematic review and meta-analysis of 24 studies found a pooled bronchiectasis prevalence of 19 percent in AAV—higher with MPO-ANCA than PR3-ANCA, at 28 percent versus 13 percent—and noted that bronchiectasis may precede, coincide with, or follow the vasculitis. One retrospective cohort of 58 AAV patients found bronchiectasis in 37.9 percent, all MPO-ANCA positive, independently associated with MPO specificity, female sex, and age at diagnosis. Most striking is a multicentre cohort of 61 patients with AAV and bronchiectasis: in 25 of them, bronchiectasis preceded the vasculitis by a median of 16 years, and this bronchiectasis-first group had more microscopic polyangiitis, more MPO-ANCA, and shorter survival. The present patient—female, MPO-positive, with airway disease antedating systemic vasculitis by seven years—fits that phenotype precisely.

Yet the authors resist a simple causal narrative, and the evidence supports their caution. Where bronchiectasis was universally MPO-associated, affected patients actually had less frequent renal involvement than those without it, and bronchiectasis in AAV generally does not respond to immunosuppression—consistent with this patient, whose consolidations melted away while the structural airway disease remained. Whether earlier serology would have changed her outcome is genuinely uncertain. The real gap, they argue, lies in the current diagnostic algorithms. The 2025 European Respiratory Society guideline strongly recommends standardized testing for the underlying cause of bronchiectasis, but ANCA appears only within an etiological algorithm gated behind systemic features—coexisting autoimmune disease, hemoptysis, or signs of vasculitis—and the guideline explicitly states these components are not separate recommendations. A 2025 observational study screening 468 bronchiectasis patients found ANCA positivity in just 3.8 percent and concluded screening should remain individualized. The 2026 American College of Chest Physicians guideline addresses management only. This patient had none of the trigger features before 2025: her gap sits outside current algorithms—culture-negative, radiographically progressive, incompletely corticosteroid-responsive disease without systemic features.

One diagnostic alternative deserved careful exclusion. The combination of MPO-ANCA positivity, long-standing airway disease, and a history of asthma raises eosinophilic granulomatosis with polyangiitis as the leading rival. Applying the 2022 ACR/EULAR classification criteria is instructive: her cumulative score was just 2 points—3 for obstructive airway disease, credited on her asthma history despite normal spirometry, minus 1 for hematuria—far below the 6 required, because the most heavily weighted item, a maximum eosinophil count of at least 1 × 10⁹ per liter, was never met. Eosinophils were 0 percent at presentation and had never been elevated; total IgE, measured in 2024, was 114 kU/L without the marked elevation characteristic of EGPA. Pauci-immune crescentic glomerulonephritis with markedly elevated MPO-ANCA and no tissue or blood eosinophilia settles the question in favor of microscopic polyangiitis. The case also carries a technical lesson in serology: the discordance between her falling MPO-ANCA titers and persistent weak immunofluorescence positivity is compatible with non-MPO perinuclear antibodies during B-cell depletion, reinforcing guidance against basing treatment decisions on titers alone. Limitations remain—alveolar hemorrhage was never definitively confirmed, and the absence of ANCA testing during the airway phase means the timing of seroconversion is unknown. What endures is the clinical message: in a patient with progressive, culture-negative bronchiectasis that resists the usual treatments, the vasculitis may already be knocking, years before the door gives way.

Subject of Research: Bronchiectasis as an early sentinel manifestation of ANCA-associated vasculitis

Article Title: Bronchiectasis as the Sentinel Manifestation of ANCA‐Associated Vasculitis: A Case Report and Literature Review

Article References: Kim, A., Vartany, C., Hegde, S., Lau, K., Tatosyan, L., & Liang, B. (2026). Bronchiectasis as the Sentinel Manifestation of ANCA ‐Associated Vasculitis: A Case Report and Literature Review. Respirology Case Reports, 14(10), Article e70777. https://doi.org/10.1002/rcr2.70777

Image Credits: AI Generated

DOI: 10.1002/rcr2.70777

Keywords: bronchiectasis, ANCA-associated vasculitis, microscopic polyangiitis, MPO-ANCA, case report, glomerulonephritis, rituximab, high-resolution CT, EGPA, clinical guidelines, autoimmune screening, respiratory medicine

The science underlying the disease is elegantly captured by what researchers call the vicious vortex, a conceptual framework building on the vicious cycle theory first proposed by Professor Peter Cole in 1986. Four interrelated factors drive the pathology: airway inflammation, impaired mucociliary clearance, airway infection, and structural lung damage. Each element feeds the others, so that infection triggers inflammation, inflammation impairs the tiny hair-like cilia that sweep mucus from the airways, stagnant secretions harbor more bacteria, and the resulting damage further distorts the airway architecture. Exacerbations accelerate this vortex. They are formally defined as a deterioration in three or more key symptoms lasting at least 48 hours, including cough, sputum volume or purulence, breathlessness, fatigue, or coughing up blood, alongside a clinician’s judgment that treatment must change. Each episode is associated with declining lung function, diminished quality of life, and increased mortality, and a history of exacerbations is itself a major predictor of future ones.

The patient at the heart of the case study illustrates just how formidable this vortex can become. Diagnosed with bronchiectasis in 2005 at age 55, he also carries diagnoses of asthma and chronic obstructive pulmonary disease, and he is an ex-smoker with 20 pack-years of history. Serial CT scans reveal extensive bilateral bronchiectasis concentrated in the mid and lower zones of his lungs, and his Bronchiectasis Severity Index score of 18 places him in a high-risk category. He suffers numerous exacerbations every year, driven by the combined burden of all three chronic lung conditions. In July 2024, he noticed the familiar warning signs: coughing up large amounts of purulent sputum, worsening breathlessness, and crushing exhaustion. Recognizing an exacerbation, he did exactly what his self-management plan advised, starting a two-week course of oral co-amoxiclav from a rescue pack kept at home and provided by his general practitioner.

That early self-treatment, which the new ERS guidelines explicitly endorse, proved insufficient. When he failed to improve, his GP prescribed a further two weeks of the same antibiotic, and still his symptoms persisted. Only when he contacted his specialist hospital team was his care escalated, and here the case illuminates a crucial structural innovation in modern British healthcare: the respiratory virtual ward. Admitted to this hospital-at-home service, the patient received close monitoring from a multidisciplinary team along with hospital-level diagnostics and interventions, including the ability to self-administer intravenous treatments in his own home. The NHS launched a national virtual wards programme in 2023 aiming to expand exactly this kind of hospital-level care at home, and evidence suggests patients often prefer it, feeling more comfortable and recovering faster in familiar surroundings while health systems relieve pressure on physical beds.

The microbiology that followed reads like a detective story. Consistent with guideline recommendations, a sputum sample had been taken at the onset of the exacerbation before antibiotics began, and it grew Proteus mirabilis, a bacterium not typically associated with bronchiectasis, sensitive to co-amoxiclav, along with Candida species, which are common commensals that usually require no targeted therapy. When oral antibiotics failed, the team switched to intravenous meropenem, one gram three times daily, self-administered at home for two weeks. Research on home intravenous therapy in bronchiectasis remains limited, but retrospective studies in adults and children suggest clinical outcomes comparable to inpatient care, with the added benefits of reduced risk of hospital-acquired infection and better quality of life. Remarkably, even intravenous meropenem failed to produce improvement, and the authors of the case report argue that the problem was likely not antimicrobial resistance but inadequate airway clearance, a reminder that antibiotics alone cannot break the vicious vortex if secretions remain trapped in damaged airways.

This is where the guidelines place enormous weight on airway clearance techniques, or ACTs, such as active cycle of breathing techniques and positive expiratory pressure devices. These interventions directly target the impaired mucociliary clearance component of the vortex, improving sputum clearance, reducing the burden of cough, lowering exacerbation risk, and improving quality of life. The ERS recommends that ACTs be adapted in frequency, intensity, and technique during exacerbations, and the patient was duly referred to physiotherapy. Yet he waited several months to see a respiratory physiotherapist, a delay the authors describe as sadly reflective of real-life disparities in access across the UK. When he finally received instruction, his first device, a positive expiratory pressure mouthpiece, proved intolerable because it triggered coughing, so he was switched to an oscillating positive expiratory pressure device with a slow expiratory phase to suppress the cough reflex, used after his COPD inhaler to open the airways first. At his six-week follow-up he reported easier clearance and thinner mucus, a small technical adjustment with a meaningful clinical payoff.

The bacterial saga continued. Two weeks after discharge he was readmitted with persistently high sputum volume, and cultures now showed a heavy growth of Pseudomonas aeruginosa, a notoriously resilient pathogen in bronchiectasis. The guidelines recommend eradication treatment for any new isolation of this organism, typically two weeks of oral or intravenous antibiotics followed by six to twelve weeks of inhaled antibiotics. The patient received two weeks of home intravenous meropenem, extended by two more weeks, plus daily hospital visits for intravenous tobramycin at three milligrams per kilogram, later escalated to five after monitoring confirmed stable kidney function. Evidence for dual antimicrobial therapy against Pseudomonas in bronchiectasis is thin, but data from cystic fibrosis populations support combining a beta-lactam with an aminoglycoside for chronic infection, always balanced against the risks of kidney and ear toxicity in older patients. By December 2024, bronchoscopy revealed Pseudomonas resistant to tobramycin, colistin, and gentamicin, confirming the eradication attempt had failed, and his treatment moved to three weeks of intravenous ceftazidime at home.

With chronic Pseudomonas infection now established, the guidelines strongly recommend long-term inhaled antibiotics, and the patient’s nebulised tobramycin prophylaxis was escalated from alternating months to continuous therapy. The guidelines also strongly recommend long-term macrolides for patients at high risk of exacerbations despite standard care, and large randomized trials such as EMBRACE and BAT have demonstrated that daily azithromycin reduces exacerbation frequency, including in patients with chronic Pseudomonas. He began 500 milligrams three times weekly, but only after screening for nontuberculous mycobacterial infection, QTc prolongation on his heart rhythm tracing, and liver and kidney abnormalities, as both the ERS and British Thoracic Society guidelines demand, with repeat checks four weeks later. He has tolerated the regimen well and remains stable, with no antibiotics needed for bronchiectasis exacerbations since March 2025 and a culture-negative sputum sample in April 2025.

The case also exposes the harder edges of long-term management. Mucoactive drugs such as hypertonic saline and carbocisteine are recommended when airway clearance alone fails to control symptoms, though a recent trial found neither significantly reduced exacerbation rates, and the patient’s own experience was mixed: years of nebulised normal saline with no evidence base, a trial of seven percent hypertonic saline that only slightly thinned his sputum, and a final refusal to restart it because the treatment burden was too great. He declined further pulmonary rehabilitation despite guideline support, and his long-term inhaled corticosteroids, discouraged for bronchiectasis itself, are appropriately continued for his asthma and COPD. His vaccination record, covering influenza, COVID-19, pneumococcal disease, respiratory syncytial virus, and shingles, exemplifies the preventive backbone the guidelines demand. The authors conclude that the new ERS guidance gives health services a benchmark for improving care, and perhaps most importantly, a lever to argue for faster access to the respiratory physiotherapy that this case shows can matter as much as any antibiotic.

Subject of Research: Real-world management of difficult bronchiectasis exacerbations guided by the 2025 European Respiratory Society guidelines

Article Title: Real‐World Management of Difficult Exacerbations of Bronchiectasis: A Case Study to Illustrate How Guidelines Can Support Best Practice

Article References: Bianca, H., Toby, C., Anand, S., & Paul, M. (2026). Real‐World Management of Difficult Exacerbations of Bronchiectasis: A Case Study to Illustrate How Guidelines Can Support Best Practice. Clinical Case Reports, 14(10), Article e73566. https://doi.org/10.1002/ccr3.73566

Image Credits: AI Generated

DOI: 10.1002/ccr3.73566

Keywords: bronchiectasis, exacerbations, ERS guidelines, Pseudomonas aeruginosa, airway clearance techniques, virtual ward, antibiotics, azithromycin, respiratory physiotherapy, mucociliary clearance, inhaled antibiotics, pulmonary rehabilitation

Volara is a respiratory therapy device designed for secretion mobilization and lung expansion, delivering what clinicians call oscillation and lung expansion therapy, or OLE. The device works through two complementary mechanisms: continuous high-frequency oscillation, which loosens and mobilizes mucus from the airways, and continuous positive expiratory pressure, which helps keep airways open and supports lung expansion. Uniquely, the system can simultaneously administer aerosolized medication through an integrated nebulizer, combining three respiratory therapies into a single unit. It is prescribed for patients with chronic respiratory conditions that impair airway clearance, including bronchiectasis, chronic obstructive pulmonary disease, cystic fibrosis, cerebral palsy, amyotrophic lateral sclerosis, muscular dystrophy, and other neuromuscular disorders. Its portability and ease of use make it suitable for home settings, allowing patients who require long-term airway clearance to receive therapy outside the hospital.

The research team, led by investigators at Mathematica with collaborators at Baxter International and Johns Hopkins School of Medicine, conducted a retrospective descriptive analysis using complete administrative claims and encounter data from the Centers for Medicare and Medicare Services Virtual Research Data Center. They identified Medicare fee-for-service and Medicare Advantage beneficiaries who initiated Volara between January 2023 and June 2025, along with Medicaid fee-for-service and managed care enrollees who started the device during calendar year 2023. Initiation was defined by the earliest claim containing the relevant healthcare procedure codes paired with a supplier identifier specific to the device. Patients needed to be at least five years old and continuously enrolled for twelve months before initiation, and Medicaid enrollees dually eligible for Medicare were excluded to avoid incomplete capture of their utilization.

The two cohorts differed dramatically in their demographic and clinical composition. The Medicare cohort comprised 391 enrollees with a mean age of approximately 68 years, of whom 63 percent were female and 78 percent were non-Hispanic White. The overwhelming majority, 93 percent, had pre-existing bronchiectasis, COPD, or neuromuscular disease, with bronchiectasis alone accounting for 36 percent and bronchiectasis combined with COPD for another 33 percent. The Medicaid cohort of 220 enrollees was strikingly younger, with a mean age of just 21 years and 72 percent under age 21. Its disease distribution was broader and different: 37 percent had bronchiectasis or COPD, but substantial proportions had cerebral palsy at 22 percent, neuromuscular disease at 18 percent, prior COVID-19 at 22 percent, and cystic fibrosis at 7 percent. The Medicaid cohort was also more racially and ethnically diverse and lived in neighborhoods with considerably higher social vulnerability, as measured by the CDC Social Vulnerability Index, with 70 percent classified as high vulnerability compared with 43 percent of Medicare patients.

To assess outcomes, the researchers classified patients into mutually exclusive disease segments and measured emergency department visits and inpatient hospitalizations for respiratory exacerbations, along with associated costs, standardized as annualized rates and per-member-per-month costs to account for varying follow-up times. Respiratory events were captured under a broad tier that included COPD, bronchiectasis, COVID-19, asthma, pneumonia, bronchitis, acute respiratory failure, and unspecified respiratory disorders. Clinical risk was assessed using the Elixhauser Comorbidity Index, while social risk was assigned at the ZIP code level. Because payment information is not reported for most Medicaid managed care encounters, the team imputed costs using fee-for-service claims, deriving average shadow prices stratified by year, state, disease segment, event type, demographics, and proxies for severity such as length of stay.

Among Medicare enrollees, the post-initiation period showed consistently lower respiratory-related emergency department use. Annual emergency visit rates fell from 26.3 to 11.0 per 100 patients, a 58 percent reduction, while associated per-member-per-month costs dropped from 21 dollars to 12 dollars, a 39 percent decline. These differences held across all disease segments, ranging from 44 percent lower among patients with both bronchiectasis and COPD to 70 to 81 percent lower in other segments. Hospitalizations also declined, though more modestly: rates fell from 41.2 to 30.4 per 100 patients, a 26 percent reduction, and hospitalization costs fell 11 percent, from 512 dollars to 456 dollars per member per month. The hospitalization improvements were not uniform, however. Patients with COPD saw rates and costs fall by 38 and 36 percent respectively, while neuromuscular disease patients showed similar rates between periods with slightly higher costs afterward.

Subgroup analyses added further nuance. Emergency department reductions appeared across both clinical risk groups and both age groups, but hospitalization patterns diverged sharply. Among Medicare patients with higher clinical risk, hospitalization rates were 33 percent lower after Volara initiation, whereas lower-risk patients actually saw rates rise 8 percent. Social vulnerability produced a similar split: patients in higher-vulnerability neighborhoods experienced 41 percent lower hospitalization rates and 49 percent lower costs post-initiation, while those in lower-vulnerability areas saw costs rise 30 percent despite modestly lower rates. By age, hospitalization rates fell 25 percent among patients 65 and older but rose 6 percent among younger Medicare beneficiaries. Because the pre-initiation period overlapped the COVID-19 pandemic for many patients, the team ran sensitivity analyses excluding COVID-19-related events, and the overall pattern of lower post-initiation utilization and costs remained qualitatively unchanged. Excluding patients with ALS from the neuromuscular segment also did not meaningfully alter the findings.

The Medicaid picture was considerably messier. Emergency department visit rates were nearly flat, at 31.4 per 100 patients before initiation versus 29.6 after, a 5 percent decline, but associated costs rose 24 percent, from 135 dollars to 168 dollars per member per month. Segment-level patterns conflicted: patients with bronchiectasis or COPD had higher emergency visit rates and dramatically higher costs afterward, neuromuscular disease patients had higher rates but lower costs, and cerebral palsy patients showed lower utilization and costs. Hospitalizations told a more favorable story, with rates 24 percent lower and costs 6 percent lower post-initiation overall, though neuromuscular disease patients again moved against the trend. The authors caution that the smaller Medicaid sample makes these exploratory results especially sensitive to noise.

The study’s limitations are substantial and the researchers are explicit about them. As a purely descriptive one-group pre/post design without a comparison group, the analysis cannot establish causation, and regression to the mean may partly explain the lower post-initiation utilization, since some patients likely began Volara after a period of heightened respiratory morbidity such as a hospitalization. Secular changes in healthcare behavior during and after the pandemic cannot be excluded, claims data contain no information on how often or how long patients actually used the device, and concomitant treatments were not examined. Roughly 80 percent of Medicaid costs were imputed, introducing additional uncertainty, and small sample sizes limit generalizability. The study was funded by Baxter, which manufactures the Volara system, though the analysis was conducted by Mathematica under a data use agreement with CMS.

Despite these caveats, the study fills a genuine gap. Prior literature on related airway clearance therapies, including high-frequency chest wall oscillation and oscillating positive expiratory pressure devices, has reported reductions in hospitalizations and costs, but economic evidence specifically for oscillation and lung expansion therapy has been sparse. By documenting who initiates Volara under public insurance and how their utilization patterns shift, the analysis provides hypothesis-generating context for clinicians and payers alike. The pronounced heterogeneity across disease segments, risk strata, and age groups suggests that any future evaluation of the device’s effectiveness will need to account for the fundamentally different populations served by Medicare and Medicaid, from older adults with smoking-related lung disease to children with genetic and neurologic conditions that impair airway clearance. The authors call for comparative study designs with appropriate confounding adjustment to determine whether the observed favorable trends among Medicare beneficiaries reflect a true treatment effect or the interplay of disease course, patient selection, and broader healthcare dynamics.

Subject of Research: Real-world healthcare utilization and costs among Medicare and Medicaid patients initiating Volara oscillation and lung expansion respiratory therapy

Article Title: Characteristics of Medicare and Medicaid Patients Initiating Volara Respiratory Therapy: A Medical Claims Study

Article References: Qi, W. M., Li, S. E., Klabnik, J. M., Dietz, S. H., Warling, G. M., Lechtzin, N., & Barna, M. J. (2026). Characteristics of Medicare and Medicaid Patients Initiating Volara Respiratory Therapy: A Medical Claims Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03762-6

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03762-6

Keywords: Volara, oscillation and lung expansion therapy, Medicare, Medicaid, bronchiectasis, COPD, healthcare resource utilization, emergency department visits, hospitalizations, medical claims, real-world evidence, respiratory therapy